Coptisine ameliorates oxidative injury in diabetic nephropathy by regulating the Nrf2 signaling pathway, and liquiritigenin inhibits diabetes-induced mesangial matrix accumulation in diabetic nephropathy by decreasing the NF-κB and NLRP3 inflammasome (Zhu et al., 2018). The gene discussed is NLRP3; the disease is diabetes mellitus.